Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global market for Duchenne muscular dystrophy (DMD) treatment reached a value of about USD 1.46 million in 2023. The industry is further expected to grow at a CAGR of approximately 12.50% in the forecast period of 2024-2032 to reach a value of around USD 4.22 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America and Europe are currently the two largest markets in the global Duchenne muscular dystrophy (DMD) treatment market as these are expected to account for a large proportion of the market in the forecast period. New product innovations, rising incidence of Duchenne muscular dystrophy, rise in the demand for early diagnosis, high healthcare expenditure, increasing investments in research and development of new treatment options, and government awareness programs are the major factors anticipated to propel the market growth in these regions. The United States is the dominant country in North America and is projected to maintain its lead due to rising disease incidence and the anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with increasing clinical trials around the world, especially in the United States and Europe.
The increasing adoption of EXONDYS 51 has driven the segment growth. EXONDYS 51 refers to the first FDA-approved Duchenne muscular dystrophy treatment for patients who suffer from a confirmed genetic mutation in the dystrophin gene, which can be treated by skipping exon 51. It helps the body make a shorter form of the dystrophin protein in some patients. The internal deletions mainly cause Duchenne muscular dystrophy in the gene for dystrophin, a protein essential for maintaining muscle cell membrane integrity. One of the potential therapeutic methods is to mask an exon close to the site where the others are missing so that the remaining exons can join together. Exon-skipping approach signifies one of the most capable therapeutic approaches that aim to restore the expression of a shorter but functional dystrophin protein.
Also, the market players are increasingly focusing on frequent launches in exon-skipping technology, which is a significant factor driving the segment and propelling the growth of the Duchenne muscular dystrophy (DMD) treatment market. For instance, In December 2019, Sarepta’s exon-skipping drug, VYONDYS 53 (golodirsen), was approved by the Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy.
Duchenne muscular dystrophy (DMD) is a hereditary condition that causes muscle weakening and deterioration. DMD is caused by a mutation in the gene that codes for the dystrophin protein, which is found in muscles. It is a rare muscular condition that usually affects men. Intellectual incapacity, muscle weakness, and walking and breathing difficulties are among the common symptoms.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on therapeutic approaches, the market is segmented into:
The several distribution channels of the market are:
The end-users of the market are:
The regional markets for the Duchenne muscular dystrophy (DMD) treatment market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
\
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The major drivers in the global Duchenne muscular dystrophy (DMD) treatment market include the introduction of novel drugs and therapies, significant support from various firms for drug research, disease-modifying therapies, and support from patient advocacy groups on the regulatory approval process. An increase in the number of clinical trials for testing the future treatment for Duchenne muscular dystrophy and a broad product pipeline are likely to drive the global market growth during the forecast period. Mutation-specific therapies are expected to emerge as a breakthrough in the treatment of Duchenne muscular dystrophy. The increasing disease burden of Duchenne muscular dystrophy, increased investments in biopharmaceutical research and development to release novel disease therapeutics, and increased DMD awareness campaigns also contribute to the market's growth. Various organisations are involved in spreading awareness and investing in research and development to find an effective treatment for this disease, contributing to the global market growth. Other factors, such as constant research on gene therapy, stem cell therapy, and exon skipping drugs for the treatment of DMD, are expected to propel the market growth of DMD treatment. Additionally, favourable reimbursement policies and government initiatives supporting target-specific therapies are anticipated to fuel the market during the forecasted period.
The report gives a detailed analysis of the following key players in the global Duchenne muscular dystrophy (DMD) treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Therapeutic Approaches |
|
Breakup by Distribution Channel |
|
Breakup by End Users |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!
In 2023, the global market attained a value of nearly USD 1.46 million.
The market is projected to grow at a CAGR of 12.50% between 2024 and 2032.
The market is estimated to witness healthy growth in the forecast period of 2024-2032 to reach USD 4.22 million by 2032.
The major drivers of the market include the rising disease incidence, anticipated launch of promising pipeline candidates, significant support from various firms for drug research, increased investments in biopharmaceutical research and development to release novel disease therapeutics, increased DMD awareness campaigns, favourable reimbursement policies and government initiatives supporting target-specific treatments.
The introduction of novel drugs and therapies and an increase in the number of clinical trials are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Based on therapeutic approaches, the market is segmented into molecular-based therapies and steroid therapy, among other therapeutic approaches. Molecular-based therapies are further divided into mutation suppression and exon skipping.
The several distribution channels of the market are hospitals, retail, and online pharmacies.
The end-users of the market are hospitals, home care settings, and clinics.
The major players in the industry include Pfizer Inc., Sarepta Therapeutics, Inc., PTC Therapeutics Inc., FibroGen, Inc, F. Hoffmann-La Roche Ltd, NS Pharma, Inc., and Solid Biosciences Inc., among others.
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Pricing Plans
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-120-433-0800
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124